JPMorgan Reiterates Overweight Rating on Biohaven Pharmaceutical Holding (BHVN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
Go back to JPMorgan Reiterates Overweight Rating on Biohaven Pharmaceutical Holding (BHVN)
May 29, 2024 7:30 AM EDT
Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE) platformBHV-1300 demonstrates dose-dependent and rapid IgG reductions within hours of administrationNo SAEs, no severe AEs, most AEs were mild, deemed unrelated to study drug and resolved spontaneouslyNo clinically significant changes in LFTs across any dose cohorts to dateHighlights advances from novel ion channel program targeting Kv7 activation and TRPM3 antagonism across multiple neurological, pain... More
May 29, 2024 7:15 AM EDT
-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the potential for broader therapeutic margin than other Trop-2 ADCs currently in development, and synergistic affects when combined with anti-PD1 therapy
-Biohaven also entered into a clinical supply agreement with Regeneron to study the combination of BHV-1510 with Regeneron's anti-PD-1 Libtayo® (cemiplimab-rwlc) in... More
